Dr Agwale has put a
lot of efforts to push this agenda forward and has
received global recognition for these laudable efforts.
He has already made several candidates DNA
vaccines, some of which have been shown to be
immunogenic in animal models. His studies on molecular
epidemiology of HIV in Nigeria led to the establishment
of subtypes A/G recombinant and G as the most
predominant subtypes in Nigeria. Dr. Agwale led the
studies that established the first molecular evidence of
HIV-2 in Nigeria. In addition, he reported the first
case of drug resistant HIV-1 in Nigeria. Dr. Agwale
spearheaded a series of studies that established a
murine model of HIV Tat-mediated immune modulation. This
model will be invaluable in allowing the identification
of novel Tat immunogens that could afford protection
against this activity of the HIV-1 Tat protein.
With
over 10 years experience combining top-level scientific
research with the operations of a private company, he
has been involved in academic research at various
institutions in Nigeria, Brazil, Germany, the UK, and
the United States. Before coming back to Nigeria, Dr.
Agwale worked for several years at the institute of
Human Virology, Baltimore, USA. Between 2001 and 2003,
he served as Head of the Vaccines/Immunology Unit of the
National Institute for Pharmaceutical Research and
Development (NIPRD) - the Nigerian federal government
Research Institute.
Dr. Agwale is West Africa's representative on HIV/AIDS
for Developing countries Coordinating Committee (DCCC)
at European and Developing Countries Clinical Trials
Programme (EDCTP), where he is also the chair of the
African Scientists committee (DCCC). He represents
African scientists at the partnership board and General
Assemble-European Economic Interest Group (GA-EEIG) of
EDCTP. Furthermore, Dr. Agwale was appointed Chairman of
the Nasarawa State’s specialist hospital, Lafia. He also
represents Nigeria and West Africa at the NEPAD Council.
He has experience in vaccine development and large
epidemiological projects management. He played a key
role in the development of the Nigerian HIV vaccine plan
and the creation of the Nigerian AIDS Vaccine Programme
(NAVAP) both of which were adopted by Nigerian
Stakeholders. In addition, he was a participant in the
development of guidelines for the use of Antiretroviral
in Nigeria. He is a member of the Nigerian National
Vaccine Plan (NNVC). In addition, Dr. Agwale currently
chairs the scientific committee of the Nigerian HIV
Vaccine and Microbicide Advocacy group (NHVMAG).
Dr. Agwale has represented Nigeria and Africa at various
local and international scientific fora including
assignment as temporary adviser to WHO/UNAIDS. In 2004
and 2005, Dr. Agwale served on the European Commission
Framework Programme 6 (FP6) grant review committee and
is currently a member of the European HIV Vaccine
Special Working Group.
He is a recipient of
several scholarships, fellowships and grants from
reputable organizations around the world. Currently, he
is the principal investigator of the International
Partnership for Microbicides (IPM) funded HIV incidence
study in Nigeria in preparation for a phase III clinical
trial of microbicides. He
has also authored and co-authored numerous noteworthy
publications.
CLICK HERE TO READ IBL's NEWS
CLICK HERE TO VIEW IBL CORPERS PROFILE
|
